JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Steiner, M
Right arrow Articles by Schuff-Werner, P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steiner, M
Right arrow Articles by Schuff-Werner, P
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*FLUOROURACIL
Medline Plus Health Information
*Nausea and Vomiting
Journal of Clinical Pathology 2005;58:553-555
© 2005 BMJ Publishing Group Ltd & Association of Clinical Pathologists


CASE REPORT

5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case

M Steiner1, M Seule1, B Steiner2, I Bauer3, M Freund2, C H Köhne2, P Schuff-Werner1

1 Institute of Clinical Chemistry and Laboratory Medicine, University of Rostock, Ernst-Heydemann-Str. 6, D-18057 Rostock, Germany
2 Division of Haematology/Oncology, Department of Internal Medicine, University of Rostock
3 Division of Medical Genetics, Children’s Hospital, University of Rostock

Correspondence to:
Dr M Steiner
Medical Faculty, Institute of Clinical Chemistry and Laboratory Medicine, University of Rostock, Ernst-Heydemann-Str. 6, D-18057 Rostock, Germany; michael.steiner{at}med.uni-rostock.de
ABSTRACT
Combination cancer chemotherapy induced toxicity can be associated with combined pharmacogenetic syndromes. Dihydropyrimidine dehydrogenase (DPD) is the principal enzyme involved in the catabolic detoxification of 5-fluorouracil (5FU). A heterozygous G > A transition at the 5' splicing donor consensus sequence in intron 14 leading to exon 14 skipping (IVS14+1 G > A, DPYD*2A) with partial loss of enzyme activity may be partly responsible for 5FU induced toxicity, whereas irinotecan associated toxicity may in part be explained by an aberrant UGT1A1 promoter (TA)n genotype underlying Gilbert’s syndrome with reduced liver glucuronidation activity. This report describes a 44 year old white woman who suffered from severe gastrointestinal and haematological toxicity while undergoing 5FU24h/folinic acid/irinotecan treatment for adenocarcinoma of the sigmoid colon. Despite appropriate supportive treatment, her condition rapidly deteriorated and led to death. Molecular analysis revealed a hitherto undescribed combined pharmacogenetic syndrome, consisting of heterozygosity for the DPD IVS14+1 G > A mutation and UGT1A1 (TA)6/7 heterozygosity, which probably contributed to the fatal outcome in this patient.


Abbreviations: DPD, dihydropyrimidine dehydrogenase; FA, folinic acid; 5FU, 5-fluorouracil

Keywords: dihydropyrimidine dehydrogenase; 5-fluorouracil; Gilbert’s syndrome; irinotecan; pharmacogenetics




This article has been cited by other articles:


Home page
Am J Health Syst PharmHome page
K. K. Hahn, J. J. Wolff, and J. M. Kolesar
Pharmacogenetics and irinotecan therapy
Am. J. Health Syst. Pharm., November 15, 2006; 63(22): 2211 - 2217.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.